NEW YORK (GenomeWeb News) – Quest Diagnostics today reported that its revenues in the first quarter dropped 6 percent year over year as it missed the average analyst estimate on both the top and bottom lines.

For the three months ended March 31, the firm brought in $1.79 billion in revenues, down from $1.91 billion a year ago and short of the $1.86 billion expected by Wall Street.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The New York Times' George Johnson muses on cancer's roots in multicellularity.

The San Diego Union Tribune wonders whether Medicare is ready for personalized medicine.

Jun Wang, the chief executive of BGI, has stepped down.

In PNAS this week: human T cell editing with CRISPR, retrotransposons acting as insulators, and more.